BerGenBio ASA
BRRGF · OTC
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.00 | -0.00 | 0.00 |
| FCF Yield | -3.76% | -359.86% | -1,068.35% | -874.87% |
| EV / EBITDA | -33.76 | 2.05 | 4.92 | 7.49 |
| Quality | ||||
| ROIC | -40.74% | -40.74% | -27.14% | -17.72% |
| Gross Margin | 100.00% | 100.00% | 100.00% | 0.00% |
| Cash Conversion Ratio | 1.36 | 1.36 | 1.27 | 1.11 |
| Growth | ||||
| Revenue 3-Year CAGR | 140.41% | 98.51% | 29.66% | -12.36% |
| Free Cash Flow Growth | 0.00% | -1.62% | -31.87% | 40.92% |
| Safety | ||||
| Net Debt / EBITDA | 2.42 | 2.42 | 5.04 | 7.63 |
| Interest Coverage | 0.00 | 0.00 | -39.35 | -15.26 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 190.55 | 178.51 | 89.74 | 0.00 |